Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA adenine N3 in the minor groove of duplex DNA is a highly specific nucleophilic site that serves as a primary target for several classes of potent antitumor antibiotics and synthetic alkylating agents (Boger & Johnson, 1995, PNAS). Unlike the more accessible major groove, the minor groove's narrow and deep structure allows for high-affinity binding of small molecules, particularly in AT-rich sequences where the N3 of adenine is exposed (Hurley, 2002, Nature Reviews Cancer). When targeted by agents such as duocarmycins or CC-1065, the N3 position undergoes covalent alkylation, a process often driven by shape-selective activation and DNA-induced conformational changes of the drug (Boger & Garbaccio, 1999, Accounts of Chemical Research). This modification is exceptionally cytotoxic because N3-adenine adducts are non-instructional and strongly block the progression of DNA polymerases, effectively halting the cell cycle (Wyatt & Pittman, 2006, Chemical Research in Toxicology). Furthermore, these adducts are unstable and can lead to the formation of abasic sites, which, if not processed by the base excision repair (BER) pathway involving alkyladenine DNA glycosylase (AAG), result in lethal double-strand breaks (O'Brien & Ellenberger, 2004, Journal of Biological Chemistry). In therapeutic applications, drugs targeting this site are designed to exploit the rapid proliferation of malignant cells, although their clinical use is often limited by severe side effects like delayed bone marrow toxicity (Tercel et al., 2013, Angewandte Chemie).
Sequence-specific DNA alkylation at the N3 position of adenine in the minor groove, leading to DNA strand distortion, inhibition of replication, and induction of apoptosis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA adenine N3 (minor groove) (N3-Ade).